Serum Hepcidin and Ferritin Have Not Correlation With Inflammatory Markers in Kidney Transplant Patients

Nayyereh Sadat Mortazavi Khorasgani1, Ali Momeni2, Soleiman Kheiri3, Rohollah Masumi2, Saeed Mardani4, Fateme Salehi Choliche1, Maryam Saeedi5, Farzad Rashidi3, Sepideh Shabani Broujeni1

1 School of Medical Sciences, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Department of Internal Medicine, School of Medical Sciences, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 Social Health Departments Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
4 Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
5 Department of Immunology, School of Medicine, University Complutense, Madrid, Spain

Abstract- In renal transplant patients, increased ferritin is associated with an increased risk of cardiovascular disease, transplant rejection, and mortality. Serum ferritin elevates in renal transplant patients due to blood product transfusion, inflammation, and malignancies. Hepcidin is also a peptide hormone produced in the liver in response to anemia, hypoxia, or inflammation. The aim of this study was to investigate the relationship between ferritin, hepcidin, iron, TIBC, and serum inflammatory markers in renal transplant patients. The cross-sectional descriptive-analytical study was conducted on 60 renal transplant patients referred to Hazrat-Rasool and Imam-Ali clinics and Al-Mahdi Laboratory of Shahrekord selected by convenience sampling method. Serum ferritin, hepcidin, iron, TIBC, and inflammatory markers levels were determined by standard kits by ELISA. Data were analyzed by SPSS software. Serum iron had a significant negative correlation with erythrocyte sedimentation rate (ESR) (r=-0.418, P=0.001) and a negative correlation with C reactive protein (CRP) (r=-0.243, P=0.061). TIBC had a significantly negative association with ferritin (r=-0.27, P=0.037). Ferritin, hepcidin, and TIBC were not significantly correlated with inflammatory factors. The results of the study showed no significant relationship between ferritin, hepcidin, and TIBC with inflammatory factors in renal transplant patients.

Keywords: Inflammatory factor; Kidney transplant; Hepcidin; Ferritin

Introduction

End-stage renal disease (ESRD) is an incurable condition associated with irreversible renal failure (1). When more than 95% of kidney tissue is destroyed for various reasons, the accumulation of toxins in the body reaches such a level that the permanent use of the alternative kidney therapies, including hemodialysis, peritoneal dialysis, or kidney transplant, must be prescribed to avoid uremia and its life-threatening complications (2). Currently, there are about 3 million patients undergoing kidney replacement therapy worldwide, and this number is expected to increase to 5-10 million by 2030 (3). The increased prevalence of obesity, diabetes, and hypertension can face the populations with even much worse situations (1). Kidney transplantation is the most important treatment for ESRD patients, which has significantly improved the life expectancy and quality of life of these patients (4). With advances in transplantation methods, acute rejection of the transplant has decreased to 15 percent, and one-year survival of individuals has increased to more than 90 percent (5).

Anemia is considered a common problem in kidney transplant patients (6) and a risk factor for cardiovascular disease (7). Anemia may be occurred in kidney transplant
patients due to renal dysfunction, iron deficiency due to drugs such as angiotensin-converting enzyme inhibitors (ACEI), mycophenolate mofetil, and azathioprine, hemolysis, erythropoiesis inhibition with uremic toxins, aluminum poisoning and bleeding (8). Human recombinant erythropoietin (rh EOP) is used for the treatment of anemia in these patients. Moreover, iron prescribing plays a key role in increasing the EOP response in kidney transplant patients (9). However, the prescribed iron should be in such a way that the serum level of ferritin does not exceed 800 ng/mL (10). Recently, ferritin levels and iron overload have been identified as predictive factors in the development and progression of atherosclerosis (11).

Hepcidin is a small peptide produced in the liver in response to anemia, hypoxia, or inflammation, which is considered to be a key regulator of iron use. The potential of measuring hepcidin in biological fluids has made serum hepcidin act as a marker of iron status better than other traditional iron indicators such as serum ferritin and transferrin saturation (12). Previous studies have shown significant correlations between high levels of hepcidin and allograft disorder, increased inflammatory markers, and higher transferrin saturation (13). Also, it is reported that in kidney transplant recipients, hepcidin has been significantly associated with ferritin, creatinine (Cr), and glomerular filtration rate (GFR) (12).

In kidney transplant patients, immune system activity increases due to the reception of allografts. In the next steps, inflammation and activation of the immune system that are directly related to atherogenesis can lead to transplant rejection (14). In this regard, previous studies have shown that inflammatory markers (including C reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin 6 (IL-6) are associated with the occurrence of acute rejection periods (15). Given the kidney damage caused by iron overload and increased inflammatory markers, which can eventually lead to chronic kidney disease (CKD) and transplant rejection, this study was designed to examine the relationship between hematological factors and inflammatory markers in kidney transplant patients.

Materials and Methods

The study was a cross-sectional descriptive-analytical study. The study population included 60 kidney transplant patients referring to Hazrat Rasool and Imam Ali Clinics and Al-Mahdi Laboratory in Shahrekord, Iran. Inclusion criteria were kidney transplantation duration greater than one year, the age range of 18 to 70 years, Cr≤1.5 mg/mL or GRF≥50 mL/min/1.73 m², and written consent to participate in the study. Exclusion criteria were malignancy and active infection, clinical evidence of heart failure, a history of iron deficiency anemia, and a reluctance to cooperate and use iron supplements or blood transfusions over the past three months.

Patients with inclusion criteria entered the study by easy and available sampling method after signing the consent form. Patients’ information and clinical history were collected based on medical history and with the help of a questionnaire. Age, sex, duration of transplantation, and type of transplant donor (live/quadrupled) were recorded. All patients underwent a standardized immunosuppressive suppression three-drug protocol, including prednisolone, cyclosporine, and mycophenolate mofetil or azathioprine.

Five milliliters of blood were taken from patients in the morning and after 12 hours of fasting. Blood samples were centrifuged at 4000 rpm for 5 min in heparin tubes, and the serum was collected and kept at −20° C until experiments.

The levels of serum ferritin, iron, total iron-binding capacity (TIBC), and CRP were measured by the BIO SYSTEM (282AA) kit (USA) using the ELISA method. Hepcidin was measured using Bioassay Technology Laboratory Kit by the ELISA method.

Results

In the present study, 60 patients with kidney transplantation aged 47.67±13.85 years entered the study. 19 (31.7%) patients were female, and the other 41 (68.3%) patients were male. The characteristics of the studied patients are shown in Table 1. The mean of inflammatory factors, iron, TIBC, ferritin, and hepcidin in kidney transplant patients are shown in Table 2.

The mean of inflammatory factors, iron, TIBC, ferritin, and hepcidin, according to the type of donor, are shown in Table 3. According to the results, ESR and CRP levels were higher in patients with live donors, while hepcidin and ferritin were higher in brain death donors. However, none of the inflammatory factors, iron, TIBC, ferritin, and hepcidin, showed a significant difference in terms of donor type (P>0.05).

The results of the Spearman correlation coefficient of inflammatory factors with iron, ferritin, TIBC, and hepcidin are presented in Table 4. Based on the results, no significant relationship was observed between ESR and CRP (r=0.086, P=0.516). Serum iron had a significant negative relationship with ESR (r=-0.418,
Variable  
(serum half renal clearance of inflammatory factors. For example, the exacerbate inflammatory responses due to decreased
transplant patients was significantly higher than
Malyszko et al. (2006), the mean serum CRP of kidney transplant patients were 82.70±29.53, 342.20±46.73, and 149.05±176.82, respectively. In a study by Malyszko et al. (2006), man serum iron and TIBC did not show any significant difference between control and kidney transplant groups. However, the mean ferritin was significantly higher in the kidney transplant group than in healthy mice (17). In the present study, the mean serum iron, TIBC, and ferritin content of kidney transplant patients were 82.70±29.53, 342.20±46.73, and 149.05±176.82, respectively.

Discussion

In our study, the mean CRP was 6.97±8.27 mg/l, and the mean ESR was 8.05±6.01. In a study conducted by Malyszko et al. (2006), the mean serum CRP of kidney transplant patients was significantly higher than that of the control group (16). Decreased renal function may exacerbate inflammatory responses due to decreased renal clearance of inflammatory factors. For example, the serum half-lives of pro-inflammatory cytokines, tumor necrosing factor-β (TNF-β), and interleukin-1 (IL-1) have been reported to be higher in mice with impaired renal function than in healthy mice (17). In the present study, the mean serum iron, TIBC, and ferritin content of kidney transplant patients were 82.70±29.53, 342.20±46.73, and 149.05±176.82, respectively. In a study by Malyszko et al. (2006), man serum iron and TIBC did not show any significant difference between control and kidney transplant groups. However, the mean ferritin was significantly higher in the kidney transplant group than in healthy mice (17).
the control group (16). Also, in a study by Jairam et al., (2010) on ESRD patients, a significant increase in ferritin was observed compared to the control group. However, there was no significant difference between serum iron in ESRD patients and the control group (18). The increased ferritin in ESRD and kidney transplant patients may be due to iron administration without an accurate assessment of iron status and repeated blood transfusions.

In our study, the mean hepcidin of kidney transplant patients was 1501.28±1584.33 pg/ml. Serum hepcidin had no significant relationship with inflammatory factors (CRP and ESR) as well as iron, ferritin, and TIBC. In this regard, paradoxical and sometimes similar findings have been reported for the relationship between hepcidin and inflammatory and hematological factors. Malyszko et al., (2006) studied patients with renal transplantation and reported that the mean serum hepcidin of patients was greater than the control group. Also, serum hepcidin was significantly associated with inflammatory factors (IL-β, TNF-α, and CRP), neutrophil count, and renal function (16). An experimental study indicated that IL-6 increased hepcidin expression (19). In a study conducted by Malyszko et al., (2005), it was observed that serum iron levels, TIBC, TSAT, red blood cell counts, hemoglobin, hematocrit, and platelet counts in hemodialysis patients were lower, but ferritin and hepcidin were higher than those of control group (20). Hemodialysis patients with erythropoietin-resistant anemia have also shown an increase in the activity of inflammatory markers, hepcidin, and ferritin (21). In another study conducted on ESRD patients, an increase in inflammatory markers (CRP, IL-6, and TNF-α), transferrin saturation (TSAT), ferritin, and hepcidin were observed compared to the control group. Also, there was a significant relationship between inflammatory markers, TSAT, hepcidin, and ferritin (18). In the study of Detivaus et al., (2013) on patients undergoing liver surgery, serum hepcidin levels had a significant association with hemoglobin and liver iron stores, but it had no significant association with CRP levels (22). In the study by Aoki et al., (2005), it was observed that the expression of hepcidin mRNA had no significant relationship with the level of inflammatory markers of the liver in HVC patients (23). In a study by Kato et al., (2008) on CKD patients, hepcidin levels had a significant relationship with ferritin, but it did not have a significant relationship with CRP (24). Dallalio et al., (2003) reported a significant positive association between hepcidin and ferritin in patients with bone marrow anemia (25). In a study conducted by Kulaksiz et al., (2004), an increase in pro-hepcidin levels was found in CKD patients despite their normal hemoglobin levels (26). In the present study, serum hepcidin levels in kidney transplant patients did not have a significant relationship with CRP and ESR. These results could be due to the small sample size, few positive CRP cases, and low CRP value in determining inflammation.

In the present study, serum hepcidin levels in kidney transplant patients were not significantly associated with ferritin, iron, and TIBC. However, serum hepcidin showed a weak negative relationship with iron (r=-0.163) and ferritin (r=-0.205), and patients with less ferritin and iron had higher hepcidin, which may indicate the relationship between anemia and hepcidin. In line with these results, in the study of Malyszko et al., (2005), in hemodialysis patients, the levels of iron, red blood cells, hemoglobin, and hematocrit decreased, while ferritin and hepcidin increased compared to the control group. Hepcidin showed a positive relationship with ferritin and a negative relationship with the number of red blood cells, hemoglobin, and hematocrit (20).

In our study, contradictory to some previous studies (16,20), no positive relationship was observed between hepcidin and ferritin. We believe that the result may be due to the lack of patients with high ferritin levels (in this study, all patients had ferritin levels below 600 ng/mL).

The results did not show any significant relationship between ferritin, hepcidin, and TIBC with inflammatory factors in kidney transplant patients. Serum iron levels were negatively associated with ESR and CRP. Serum hepcidin levels showed a weak negative relationship with iron and ferritin, and patients with less ferritin and iron level had higher hepcidin, which may indicate a link between anemia and hepcidin.

References

1. Peters F, Westphal C, Kramer A, Westerman R. Is the rise in the Prevalence of renal replacement Therapy at Older ages the Price for living longer? Front Public Health 2018;6:138.
2. Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M, Alberta Kidney Disease Network. Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA 2008;299:793-805.
3. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:1975-82.
4. Foronciewicz B, Mucha K, Florczak M, Szymańska A, Cisyk M, Durlik M, et al. Long-term outcome of renal transplantation: a 10-year follow-up of 765 recipients. Pol Arch Intern Med 2019;29;129:476-83.
5. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011;378:1428-37.
6. Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Babooolal K, Eklund B, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplantat 2003;3:835-45.
7. Briggs JD. Causes of death after renal transplantation. Nephrol Dialysis Transplant 2001;16:1545-9.
8. Zheng S, Coyne DW, Joist H, Schuessler R, Godboldo-Brooks A, Ercole P, et al. Iron deficiency anemia and iron losses after renal transplantation. Transplant Int 2009;22:434-40.
9. Kalantar-Zadeh K, Höfken B, Wünsch H, Fink H, Kleiner M, Luft FC. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995;26:292-9.
10. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004;19:141-9.
11. Badiou S, Cristol JP, Mourad G. Dyslipidemia following kidney transplantation: diagnosis and treatment. Curr Diabetes Rep 2009;9:305-11.
12. Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol 2010;5:1681-9.
13. Chan W, Ward DG, McClean A, Bosch JA, Jones D, Kaur O, et al. The role of hepcidin-25 in kidney transplantation. Transplantation 2013;95:1390-5.
14. Fink JC, Onuigbo MA, Blahut SA, Christenson RH, Mann D, Bartlett ST, et al. Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. Am J Kidney Dis 2002;39:1096-101.
15. Newstead CG, Lamb WR, Brenchley PE, Short CD. Serum and urine IL-6 and TNF-alpha in renal transplant recipients with graft dysfunction. Transplantation 1993;56:831-5.
16. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am J Hematol 2006;81:832-7.
17. Belmelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993;150:2007-17.
18. Jairam A, Das R, Aggarwal PK, Kohli HS, Gupta KL, Sakhuja V, et al. Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. Indian J Nephrol 2010;20:125-31.
19. Hsu SP, Chiang CK, Chien CT, Hung KY. Plasma prohepcidin positively correlates with hematocrit in chronic hemodialysis patients. Blood Purif 2006;24:311-6.
20. Malyszko J, Malyszko JS, Hrysztok T, Pawlak K, Mysliwiec M. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am J Nephrol 2005;25:586-90.
21. Malyszko J, Malyszko JS, Mysliwiec M. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation. Ren Fail 2009;31:544-8.
22. Détivaud L, Nemeth E, Boudjema K, Turlin B, Troade MB, Leroyer P, et al. Heparidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005;106:746-8.
23. Aoki CA, Rossaro L, Ramsamooj R, Brandhagen D, Burritt MF, Bowlus CL. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J Clin Gastroenterol 2005;39:71-4.
24. Kato A, Tsujii T, Luo J, Sakao Y, Yasuda H, Hishida A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008;28:115-21.
25. Dallalio G, Fleury T, Means RT. Serum hepcidin in clinical specimens. Br J Haematol 2003;122:996-1000.
26. Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, et al. Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004;53:735-43.